McKesson (NYSE:MCK) Price Target Raised to $925.00

McKesson (NYSE:MCK) had its price target lifted by analysts at Wells Fargo & Company from $914.00 to $925.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Wells Fargo & Company‘s price target indicates a potential downside of 2.88% from the stock’s previous close.

A number of other equities research analysts have also issued reports on MCK. Evercore ISI restated an “outperform” rating and issued a $1,000.00 target price on shares of McKesson in a research note on Thursday, November 6th. Robert W. Baird set a $968.00 target price on McKesson in a research report on Wednesday, January 14th. UBS Group raised their price target on shares of McKesson from $920.00 to $980.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. Weiss Ratings restated a “buy (a-)” rating on shares of McKesson in a report on Monday, December 29th. Finally, Jefferies Financial Group increased their price target on shares of McKesson from $820.00 to $900.00 and gave the company a “buy” rating in a report on Monday, October 13th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, McKesson currently has a consensus rating of “Moderate Buy” and a consensus price target of $918.93.

McKesson Stock Performance

MCK traded up $130.43 during trading on Thursday, hitting $952.43. The stock had a trading volume of 1,194,716 shares, compared to its average volume of 666,672. The company’s 50-day moving average price is $825.54 and its 200 day moving average price is $776.66. McKesson has a twelve month low of $570.51 and a twelve month high of $964.94. The firm has a market capitalization of $117.56 billion, a P/E ratio of 29.63, a PEG ratio of 1.40 and a beta of 0.40.

McKesson (NYSE:MCK) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $9.34 EPS for the quarter, beating analysts’ consensus estimates of $9.19 by $0.15. The firm had revenue of $106.16 billion for the quarter, compared to analysts’ expectations of $105.98 billion. McKesson had a net margin of 1.04% and a negative return on equity of 248.14%. The firm’s revenue was up 11.4% on a year-over-year basis. During the same period in the prior year, the company earned $8.03 EPS. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. As a group, equities analysts expect that McKesson will post 32.77 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Thomas L. Rodgers sold 276 shares of the company’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $816.18, for a total value of $225,265.68. Following the sale, the executive vice president directly owned 2,268 shares of the company’s stock, valued at approximately $1,851,096.24. This represents a 10.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CAO Napoleon B. Rutledge, Jr. sold 329 shares of the stock in a transaction on Friday, November 7th. The stock was sold at an average price of $861.63, for a total value of $283,476.27. Following the completion of the transaction, the chief accounting officer owned 328 shares in the company, valued at approximately $282,614.64. This represents a 50.08% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 0.08% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. increased its position in shares of McKesson by 0.6% in the 4th quarter. Vanguard Group Inc. now owns 12,104,719 shares of the company’s stock valued at $9,929,380,000 after acquiring an additional 73,109 shares during the period. State Street Corp increased its stake in shares of McKesson by 0.9% during the third quarter. State Street Corp now owns 5,750,519 shares of the company’s stock worth $4,447,110,000 after purchasing an additional 51,510 shares in the last quarter. Geode Capital Management LLC increased its position in shares of McKesson by 4.1% during the second quarter. Geode Capital Management LLC now owns 2,820,724 shares of the company’s stock worth $2,057,065,000 after purchasing an additional 112,224 shares in the last quarter. Franklin Resources Inc. raised its holdings in McKesson by 3.5% in the 3rd quarter. Franklin Resources Inc. now owns 2,681,321 shares of the company’s stock valued at $2,071,428,000 after acquiring an additional 90,948 shares during the last quarter. Finally, Alliancebernstein L.P. boosted its position in shares of McKesson by 5.6% during the 3rd quarter. Alliancebernstein L.P. now owns 2,394,699 shares of the company’s stock valued at $1,850,001,000 after acquiring an additional 126,684 shares during the last quarter. Institutional investors own 85.07% of the company’s stock.

McKesson News Roundup

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: Q3 results: McKesson reported EPS above consensus ($9.34) and revenue up ~11.4% year‑over‑year — a core trigger for the rally. McKesson Q3 results (MarketBeat)
• Positive Sentiment: Company raised full‑year adjusted EPS guidance to $38.80–$39.20 (above consensus), signaling confidence in profit momentum. Business Wire: McKesson raises full‑year guidance
• Positive Sentiment: Management and reporters point to strong specialty and oncology drug distribution as the growth driver behind the upgraded profit outlook. Reuters: McKesson boosts 2026 forecast
• Neutral Sentiment: Mizuho nudged its price target slightly higher to $885 but kept a “neutral” rating — a modest house view that doesn’t endorse a buy/sell shift. Benzinga: Mizuho price target update
• Neutral Sentiment: Investor resources (earnings transcript, slide deck, conference call) were posted — useful for diligence but not new fundamental news. Seeking Alpha: Earnings transcript
• Neutral Sentiment: McKesson completed its exit from the European market — a strategic move whose net impact on margins and growth is mixed and depends on redeployment of capital. HMENews: McKesson exits Europe
• Negative Sentiment: Operating cash flow weakened materially in the quarter (reported declines in cash from operations), a potential red flag for free cash flow conversion despite higher reported earnings. QuiverQuant: Weak operating cash flow
• Negative Sentiment: Recent insider selling (multiple disclosed sales) may concern some investors about near‑term insider conviction. QuiverQuant: Insider transactions
• Negative Sentiment: Median analyst price target data cited in coverage sits below the current market price (some variability across firms), implying some analysts view upside as limited at current levels. QuiverQuant: Analyst targets & ratings

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.